Daily Medication Pearl: Obeticholic Acid (Ocaliva)
May 13th 2022Obeticholic acid (Ocaliva) is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
Read More
FDA Grants Breakthrough Therapy Designation to Repotrectinib for ROS1-Positive Metastatic NSCLC
May 12th 2022Repotrectinib awarded breakthrough therapy designation for patients with ROS1-positive metastatic non–small cell lung cancer previously treated with a ROS1 tyrosine kinase inhibitor and who were not previously administered platinum-based chemotherapy.
Read More
Pharmacists Play Role in Pharmacogenomics Clinical Services
They should consider many factors and use clear guidance on predicting phenotypes from genotypes to intervene optimally based on specific drug-gene interactions.
Read More
Assessing Specialty Pharmaceutical Trends Reshaping the Field for the Future
May 11th 2022Doug Long, vice president, Industry Relations, IQVIA, discusses notable trends reshaping specialty pharmaceutical channels and the impact of these developments on the role of the pharmacist in the health care team.
Watch
Clinical Overview: PT027 for Exacerbation Risk Reduction, Improved Lung Function in Asthma
May 11th 2022The combination of albuterol/budesonide shows promise in lowering the risk of severe exacerbations and improved lung function compared to albuterol as a rescue inhaler in patients with asthma.
Read More